A phase II trial to evaluate the efficacy and safety of bevacizumab in combination with capecitabine (Xeloda) in frail patients with untreated metastatic colorectal cancer
Latest Information Update: 13 Feb 2017
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2017 Status changed from active, no longer recruiting to completed.
- 03 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Feb 2011 Planned end date changed from 1 Feb 2009 to 1 Feb 2012 as reported by ClinicalTrials.gov.